- Home
- TOPS vs SCYX Comparison
TOPS vs SCYX Comparison
Compare TOPS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- SCYX
- Stock Information
- Founded
- TOPS 2000
- SCYX 1999
- Country
- TOPS Greece
- SCYX United States
- Employees
- TOPS N/A
- SCYX N/A
- Industry
- TOPS Marine Transportation
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- SCYX Health Care
- Exchange
- TOPS Nasdaq
- SCYX Nasdaq
- Market Cap
- TOPS 27.4M
- SCYX 28.5M
- IPO Year
- TOPS 2004
- SCYX 2014
- Fundamental
- Price
- TOPS $5.89
- SCYX $0.71
- Analyst Decision
- TOPS
- SCYX
- Analyst Count
- TOPS 0
- SCYX 0
- Target Price
- TOPS N/A
- SCYX N/A
- AVG Volume (30 Days)
- TOPS 141.9K
- SCYX 114.5K
- Earning Date
- TOPS 08-08-2025
- SCYX 08-07-2025
- Dividend Yield
- TOPS N/A
- SCYX N/A
- EPS Growth
- TOPS N/A
- SCYX N/A
- EPS
- TOPS 1.09
- SCYX N/A
- Revenue
- TOPS $86,127,000.00
- SCYX $2,630,000.00
- Revenue This Year
- TOPS $9.90
- SCYX $463.61
- Revenue Next Year
- TOPS N/A
- SCYX $310.80
- P/E Ratio
- TOPS $5.41
- SCYX N/A
- Revenue Growth
- TOPS 3.83
- SCYX N/A
- 52 Week Low
- TOPS $5.00
- SCYX $0.66
- 52 Week High
- TOPS $11.47
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- TOPS 47.12
- SCYX 39.12
- Support Level
- TOPS $5.10
- SCYX $0.66
- Resistance Level
- TOPS $5.74
- SCYX $0.75
- Average True Range (ATR)
- TOPS 0.75
- SCYX 0.05
- MACD
- TOPS -0.10
- SCYX -0.00
- Stochastic Oscillator
- TOPS 24.32
- SCYX 25.16
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.